MBRX

Moleculin Biotech Inc

Add to Watchlist

Advanced Chart

0.665

+0.037(5.892%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.6899

Open

0.600

VWAP

0.64

Vol

2.13M

Mkt Cap

20.09M

Low

0.592

Amount

1.37M

EV/EBITDA(TTM)

Total Shares

2.31M

11.25M

EV/OCF(TTM)

P/S(TTM)

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

3 Analyst Rating

952.47% Upside

Wall Street analysts forecast MBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 7.00 USD with a low forecast of 4.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

952.47% Upside

Current: 0.665

Low

4.00

Averages

7.00

High

13.00

952.47% Upside

Current: 0.665

Low

4.00

Averages

7.00

High

13.00

Roth Capital

Jonathan Aschoff

Buy

downgrade

$20 -> $13

2025-06-27

Reason

Roth Capital

Jonathan Aschoff

Price Target

$20 -> $13

2025-06-27

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Moleculin Biotech to $13 from $20 and keeps a Buy rating on the shares following the recent capital raise. The firm cites financial model adjustments for the target cut. Roth believes Moleculin's warrant exercise should be able to fund operations to the end of 2025, given the MIRACLE trial unblinded initial interim data announcement from 45 patients that it expects in the second half of 2025.

H.C. Wainwright

initiated

2025-06-09

Reason

H.C. Wainwright

Price Target

2025-06-09

initiated

Reason

H.C. Wainwright assumed coverage of Moleculin Biotech with a Buy rating and $4 price target. Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

2025-03-25

Reason

Maxim Group

Jason McCarthy

Price Target

2025-03-25

Upgrades

Hold

Strong Buy

Reason

Maxim analyst Jason McCarthy upgraded Moleculin Biotech to Buy from Hold with a $4 price target.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-03-25

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-25

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-03-24

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Maintains

2025-03-03

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-03

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Moleculin Biotech Inc (MBRX.O) is -0.47, compared to its 5-year average forward P/E of -1.77. For a more detailed relative valuation and DCF analysis to assess Moleculin Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.77

Current PE

-0.47

Overvalued PE

-0.05

Undervalued PE

-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.26

Undervalued EV/EBITDA

-0.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00